Startups
Salmedix was a start-up biotechnology firm focused on discovering and developing minimally-toxic therapies to treat cancers, particularly those that affect the growing global geriatric population. The company was acquired by Cephalon in May 2005.
Investors 3
| Date | Name | Website |
| Sign up to see | Sign up to see | Sign up to see |
| Ben Franklin Technology Partner of Southeastern Pennsylvania | sep.benfranklin.org | |
| Oak Investment Partners | oakvc.com |
Mentions in press and media 3
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 8, 2011 | FDA’s REMS program puts BDSI at a disadvantage in cancer drug market | BDSI has been working with the FDA on changes to get its lead product on the same footing as its competitors. While BDSI had hoped to finish those changes in the second quarter, now it looks like it will be a little bit longer. Vice preside... |
| FDA’s REMS program puts BDSI at a disadvantage in cancer drug market | Commercializing a new drug in the face of strict U.S. Food and Drug Administration guidelines is tough. It’s even tougher when direct competitors don’t have those same limits. That’s the situation facing Raleigh, North Carolina-based BioDel... |
Reviews 0
FAQ about Cephalon
Who has invested in Cephalon?
Parsers VC lists 3 investors of Cephalon, among them Ben Franklin Technology Partner of Southeastern Pennsylvania and Oak Investment Partners.
What has the press written about Cephalon?
Parsers VC has collected 3 articles mentioning Cephalon, among them “FDA’s REMS program puts BDSI at a disadvantage in cancer drug market” (Jun 8, 2011) and “FDA’s REMS program puts BDSI at a disadvantage in cancer drug market”.
Is Cephalon still active?
Cephalon is probably closed: its latest activity on Parsers VC dates from Mar 8, 2024.